A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT03841448 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class

Stopped Study was terminated early having identified clinically meaningful magnitude of proteinuria reduction due to cemdisiran (study goal). Participants completed DBT period\&were in OLE period. Sponsor had no concerns with safety\&integrity of participants.

Conditions

Interventions

Sponsor

Alnylam Pharmaceuticals